UroGen Pharma (URGN) Operating Leases (2019 - 2026)

UroGen Pharma (URGN) has 8 years of Operating Leases data on file, last reported at $5.6 million in Q1 2026.

• Quarterly Operating Leases rose 98.77% year-over-year to $5.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.6 million (up 98.77% YoY) and the FY2025 annual result came in at $6.1 million, up 270.36% from the prior year.
• Operating Leases slipped to $5.6 million in Q1 2026, from $6.1 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $6.2 million in Q3 2025 to a low of $844000.0 in Q4 2023.
• A 5-year average of $2.7 million and a median of $2.3 million in 2022 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2022 — Operating Leases jumped 534.92% — and 2023, when it sank 66.6%.
• Tracing URGN's Operating Leases over 5 years: stood at $2.5 million in 2022, then slumped by 66.6% to $844000.0 in 2023, then soared by 95.85% to $1.7 million in 2024, then jumped by 270.36% to $6.1 million in 2025, then retreated by 7.76% to $5.6 million in 2026.
• The last three Operating Leases figures came in at $5.6 million (Q1 2026), $6.1 million (Q4 2025), and $6.2 million (Q3 2025), per Business Quant data.